Everand Logo

Welcome to Everand!

  • Discover this podcast and so much more

    Podcasts are free to enjoy without a subscription. We also offer ebooks, audiobooks, and so much more for just $11.99/month.

    ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

    ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

    FromNeurology Today in 5

    Start listeningView podcast show

    ME/CFS and long COVID; negative outcomes for ALS drug; donanemab

    FromNeurology Today in 5

    ratings:
    Length:
    5 minutes
    Released:
    Apr 18, 2024
    Format:
    Podcast episode

    Description

    Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
    Released:
    Apr 18, 2024
    Format:
    Podcast episode

    Titles in the series (99)

    Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today provides an overview of topics covered in the latest issue.